ArticleThe British journal of radiology2025
PREDICTing Post-Embolization Syndrome after uterine fibroid embolization: the PREDICT-PES study.
Article in The British journal of radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Prospective evaluation of uterine artery embolization using diluted NBCA-lipiodol mixture for uterine fibroids: preliminary treatment outcomes.CVIR endovascular · 2026Article
- The Three Key Phases of Post-embolisation Syndrome After Uterine Artery Embolisation: A Proposed Nomenclature.Cardiovascular and interventional radiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo identify the rate of clinically significant post-embolization syndrome (csPES) in our cohort of patients after uterine artery embolization (UAE) for symptomatic fibroids and to identify risk factors associated with the development of csPES.
methodsRetrospective case-control study. All patients who underwent UAE for symptomatic fibroids between the 18-month period of March 1, 2022 and September 1, 2023 were recruited. csPES was defined as maximum pain score on visual analogue scale of >5 out of 10, plus at least 1 of: morphine patient-controlled analgesia dose >10 mg, fever, or use of 2 or more antiemetics.
resultsA total of 69 patients were included, mean age 46.2 years, and median uterine volume 393 mL (range 80-2288 mL). The rate of csPES was 47.8% (33 patients). After adjusting for confounding using multiparametric logistic regression, a positive association was seen between nulliparity and developing csPES (OR: 5.51, 95% CI: 1.297-23.410, P = .021). In addition, a trend was shown between increasing age and a reduced odds of developing csPES (OR: 0.87, 95% CI: 0.748-1.002, P = .054).
conclusionThe rate of csPES in our cohort was 47.8%, and nulliparity was strongly associated with the development of csPES. We can use this to better counsel our patients regarding the odds of csPES when these risks are present at pre-procedure consultation and target additional interventions at reducing csPES in this population. ADVANCES IN KNOWLEDGE: Clinically significant post-embolization syndrome is common after UAE for symptomatic fibroids. This study showed that nulliparity is a risk factor for developing, previously not known or reported.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.